Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 11, 2026
DataAggregated Company Financials
Companies20
  • 7D3.7%
  • 3M11.4%
  • 1Y-39.8%
  • YTD-14.3%

Over the last 7 days, the Healthcare industry has dropped 1.9%, driven by Zealand Pharma declining 5.5%. Overall the industry is down 42% in 12 months. Looking forward, earnings are forecast to grow by 3.2% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 11 Jun 2026DKK 1.7tDKK 468.9bDKK 147.1b19.6x11.4x3.6x
Sat, 09 May 2026DKK 1.7tDKK 467.5bDKK 148.5b20.8x11.5x3.6x
Mon, 06 Apr 2026DKK 1.5tDKK 447.8bDKK 130.1b17.4x11.3x3.3x
Wed, 04 Mar 2026DKK 1.5tDKK 448.2bDKK 131.1b17.5x11.1x3.2x
Fri, 30 Jan 2026DKK 2.1tDKK 453.2bDKK 136.7b17.5x15.6x4.7x
Sun, 28 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Tue, 25 Nov 2025DKK 1.8tDKK 454.3bDKK 137.1b17.4x13x3.9x
Thu, 23 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.9x14.4x4.5x
Sat, 20 Sep 2025DKK 2.2tDKK 447.3bDKK 141.7b19x15.7x5x
Mon, 18 Aug 2025DKK 1.9tDKK 444.4bDKK 140.2b28.1x13.6x4.3x
Wed, 16 Jul 2025DKK 2.4tDKK 423.3bDKK 124.5b29.9x19.1x5.6x
Fri, 13 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.2x22.4x6.6x
Sun, 11 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Tue, 08 Apr 2025DKK 2.4tDKK 409.5bDKK 121.3b21.9x19.5x5.8x
Thu, 06 Mar 2025DKK 3.3tDKK 409.9bDKK 121.4b27.7x27.4x8.1x
Sat, 01 Feb 2025DKK 3.3tDKK 387.7bDKK 111.4b28.8x29.2x8.4x
Mon, 30 Dec 2024DKK 3.4tDKK 387.4bDKK 111.3b29.9x30.1x8.7x
Wed, 27 Nov 2024DKK 3.9tDKK 387.4bDKK 111.3b31x35.2x10.1x
Fri, 25 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b33.7x38x10.9x
Sun, 22 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Tue, 20 Aug 2024DKK 4.7tDKK 370.7bDKK 107.0b37.4x43.8x12.6x
Thu, 18 Jul 2024DKK 4.7tDKK 355.2bDKK 106.2b35.3x43.8x13.1x
Sat, 15 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Mon, 13 May 2024DKK 4.5tDKK 354.9bDKK 106.0b34.6x42.5x12.7x
Wed, 10 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b37.3x44.2x12.9x
Fri, 08 Mar 2024DKK 4.7tDKK 341.1bDKK 99.6b38.9x47.3x13.8x
Sun, 04 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Tue, 02 Jan 2024DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.4x11.3x
Thu, 30 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b33x39.9x11.2x
Sat, 28 Oct 2023DKK 3.4tDKK 305.6bDKK 82.3b26.6x41.5x11.2x
Mon, 25 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.8x41.3x11.1x
Wed, 23 Aug 2023DKK 3.4tDKK 303.7bDKK 81.3b38.4x41.4x11.1x
Fri, 21 Jul 2023DKK 3.0tDKK 287.0bDKK 75.4b40.5x39.9x10.5x
Sun, 18 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Price to Earnings Ratio

40.3x


Total Market Cap: DKK 3.0tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.0x which is lower than its 3-year average PE of 29.8x.
  • The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.53%
Healthcare3.66%
Life Sciences7.76%
Pharma3.98%
Biotech3.23%
Healthtech2.13%
Medical Equipment1.19%
Healthcare Services-2.71%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.1x.
    • Analysts are expecting annual earnings growth of 20.1%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.4% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 283.104.2%
+DKK 50.1b		-45.2%PE10.3x
GMAB GenmabDKK 1.61k5.5%
+DKK 5.2b		8.3%PE18.6x
ALK B ALK-AbellóDKK 268.602.4%
+DKK 1.4b		43.3%PE46.5x
DEMANT DemantDKK 253.802.2%
+DKK 1.1b		-11.9%PE22.6x
COLO B ColoplastDKK 383.101.1%
+DKK 900.7m		-40.2%PE41x

Latest News

NOVO B
DKK 283.10
Novo Nordisk
7D
4.2%
1Y
-45.2%
GUBRA
DKK 356.40
Gubra
7D
7.9%
1Y
-33.9%
Narrative Update • Jun 10

GUBRA: Phase 2 Obesity Candidate Progress Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions. What's in the News Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, an investigational triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases.
GMAB
DKK 1,608.00
Genmab
7D
5.5%
1Y
8.3%
Narrative Update • Jun 10

GMAB: 2026 Readouts And Commercial Pivot Will Shape Bullish Outlook

Genmab’s consensus analyst price target has been reset lower from DKK 2,233 to DKK 2,313, with analysts citing a more commercially focused platform, evolving assumptions for revenue growth and margins, and updated P/E expectations following recent research on key pipeline readouts and price target revisions. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the product pipeline and caution around valuation assumptions and execution risks.
ZEAL
DKK 283.40
Zealand Pharma
7D
-5.3%
1Y
-41.6%
HLUN B
DKK 44.70
H. Lundbeck
7D
1.1%
1Y
12.9%
Narrative Update • Jun 06

HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple

Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.
EMBLA
DKK 26.75
Embla Medical hf
7D
-1.1%
1Y
-21.3%
Narrative Update • Jun 06

EMBLA: Ongoing Buybacks And Share Cancellations Will Support Future Upside

Analysts have kept their DKK price target for Embla Medical hf. broadly unchanged, with only a marginal adjustment driven by a slightly lower discount rate and a small tweak to the assumed future P/E multiple.
DEMANT
DKK 253.80
Demant
7D
2.2%
1Y
-11.9%
Narrative Update • Jun 05

DEMANT: Raised Fair Value And EU AI Rules May Shape Re Rating

Analysts have lifted the fair value estimate for Demant from DKK 229.83 to DKK 240.32. This reflects updated targets from firms such as Deutsche Bank and Morgan Stanley and is supported by assumptions for slightly higher revenue growth, improved profit margins, and a modestly lower discount rate, while keeping future P/E expectations broadly unchanged.
COLO B
DKK 383.10
Coloplast
7D
1.1%
1Y
-40.2%
ALK B
DKK 268.60
ALK-Abelló
7D
2.4%
1Y
43.3%
Narrative Update • May 29

ALK B: Future Upside Will Come From Allergy Immunotherapy Leadership

Analysts have lifted their price target on ALK-Abelló from DKK 263.33 to DKK 297.50, citing the company’s position as a global leader in allergy immunotherapy and recent supportive research coverage. Analyst Commentary Analysts setting a DKK 305 price target frame ALK-Abelló as a global leader in allergy immunotherapy, and they use that positioning to support a constructive view on the stock’s long term potential.
SMSMED
DKK 2.87
Scandinavian Medical Solutions
7D
-2.7%
1Y
-37.3%
BIOPOR
DKK 1.13
BioPorto
7D
-13.7%
1Y
-19.9%
CHEMM
DKK 382.00
ChemoMetec
7D
7.6%
1Y
-31.7%
PEG
DKK 0.065
Pharma Equity Group
7D
-10.4%
1Y
-41.8%
STRAP
DKK 565.00
Strategic Partners
7D
-2.6%
1Y
-44.3%